These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 26290064)

  • 21. Compulsive buying treatment with topiramate, a case report.
    Guzman CS; Filomensky T; Tavares H
    Braz J Psychiatry; 2007 Dec; 29(4):383-4. PubMed ID: 18200404
    [No Abstract]   [Full Text] [Related]  

  • 22. Endophenotypes and serotonergic polymorphisms associated with treatment response in obsessive-compulsive disorder.
    Corregiari FM; Bernik M; Cordeiro Q; Vallada H
    Clinics (Sao Paulo); 2012; 67(4):335-40. PubMed ID: 22522758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment-resistant anxiety disorders: A literature review of drug therapy strategies].
    Ammar G; Naja WJ; Pelissolo A
    Encephale; 2015 Jun; 41(3):260-5. PubMed ID: 25439852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of topiramate in alcohol dependence.
    Raguraman J; Priyadharshini RK; Chandrasekaran R
    Aust N Z J Psychiatry; 2005 Aug; 39(8):736-7. PubMed ID: 16050929
    [No Abstract]   [Full Text] [Related]  

  • 25. Addition of trazodone to sertraline: a probable synergistic action in a case of obsessive-compulsive disorder.
    Rocha FF; Corrêa H; Lage NV
    Braz J Psychiatry; 2007 Dec; 29(4):381-2. PubMed ID: 18200402
    [No Abstract]   [Full Text] [Related]  

  • 26. Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study.
    Koponen H; Lepola U; Leinonen E; Jokinen R; Penttinen J; Turtonen J
    Acta Psychiatr Scand; 1997 Nov; 96(5):343-6. PubMed ID: 9395151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder.
    Kumar TC; Khanna S
    Aust N Z J Psychiatry; 2000 Jun; 34(3):527-8. PubMed ID: 10881981
    [No Abstract]   [Full Text] [Related]  

  • 28. Topiramate-induced psychosis.
    Kober D; Gabbard GO
    Am J Psychiatry; 2005 Aug; 162(8):1542. PubMed ID: 16055782
    [No Abstract]   [Full Text] [Related]  

  • 29. Topiramate augmentation in patients with resistant major depressive disorder: a double-blind placebo-controlled clinical trial.
    Mowla A; Kardeh E
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):970-3. PubMed ID: 21291943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparing escitaloipram with sertraline for obsessive and compulsive symptoms in patients with obsessive compulsive disorder: A comparative double blind clinical trial.
    Mowla A; Modarresi F; Dastgheib SA
    Asian J Psychiatr; 2018 Dec; 38():92-95. PubMed ID: 29158148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluvoxamine: new indication. No progress in obsessive-compulsive disorder.
    Prescrire Int; 2004 Oct; 13(73):163-5. PubMed ID: 15499694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using secondary binding properties to select a not so selective serotonin reuptake inhibitor.
    Stahl SM
    J Clin Psychiatry; 1998 Dec; 59(12):642-3. PubMed ID: 9921697
    [No Abstract]   [Full Text] [Related]  

  • 33. A double-blind combination study of clonazepam with sertraline in obsessive-compulsive disorder.
    Crockett BA; Churchill E; Davidson JR
    Ann Clin Psychiatry; 2004; 16(3):127-32. PubMed ID: 15517844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Topiramate for the treatment of kleptomania: a case series and review of the literature.
    Dannon PN
    Clin Neuropharmacol; 2003; 26(1):1-4. PubMed ID: 12567156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term treatment retention with topiramate.
    Deckers CL; Renier WO
    Epilepsia; 2001 Feb; 42(2):290-1. PubMed ID: 11240609
    [No Abstract]   [Full Text] [Related]  

  • 36. Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation.
    Pallanti S; Bernardi S; Antonini S; Singh N; Hollander E
    Eur Neuropsychopharmacol; 2014 Mar; 24(3):375-80. PubMed ID: 24406025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical efficacy of citalopram in patients with obsessive-compulsive disorder].
    Jakitowicz J; Nowicki Z; Wiśniewski G
    Psychiatr Pol; 2002; 36(6 Suppl):297-301. PubMed ID: 12647452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients.
    Marazziti D; Golia F; Consoli G; Presta S; Pfanner C; Carlini M; Mungai F; Catena Dell'osso M
    CNS Spectr; 2008 Nov; 13(11):971-6. PubMed ID: 19037176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Selective serotonin reuptake inhibitors--current knowledge].
    Dudek D; Zieba A; Siwek M; Wróbel A
    Psychiatr Pol; 2004; 38(3):507-24. PubMed ID: 15199659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of topiramate adjunctive treatment added to antidepressants in patients with resistant obsessive-compulsive disorder.
    Rubio G; Jiménez-Arriero MA; Martínez-Gras I; Manzanares J; Palomo T
    J Clin Psychopharmacol; 2006 Jun; 26(3):341-4. PubMed ID: 16702907
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.